ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Modified PseudoUridines Open up Limitless Possibilities for COVID-19 mRNA Vaccines

According to the latest market report, BOC Sciences, with the yearly output of pseudoUridines and 1-methylpseudoUridines exceeding 500 kg and 1000 kg respectively, now grows to be the largest supplier around the world. What do such data stand for in the tough times overwhelmed by COVID-19? An article entitled The Critical Contribution of PseudoUridine to mRNA COVID-19 Vaccines has specified some background information.

This article argues that the presence of a critical RNA modification (N1-methyl-pseudoUridine) in mRNA vaccines can bring striking improvements in efficacy. For instance, the Pfizer-BioNTech and Moderna’s mRNA vaccines consisting of N1-methyl-pseudoUridine-modified mRNA encoding the SARS-COVID-19 spike protein and delivered with a lipid nanoparticle (LNP) formulation present efficacy higher than 90%.

There is an extensive list of pseudoUridines and derivatives in BOC Sciences' product inventory, embracing both naturally occurring and chemically synthesized ones.

Four pseudoUridine derivatives are discovered in natural RNA modification, including 1-methylpseudoUridine, 3-methylpseudoUridine, 2′-O-methylpseudoUridine, and a hypermodified residue 1-methyl-3-(3-amino-3-carboxypropyl) pseudoUridine. "Thankfully, we are in a position to manufacture all of them based on the thorough experimental and theoretical investigation into pseudoUridine structures," the technical advisor of BOC Sciences said. In addition, BOC Sciences is also equipped with versatile chemical synthesis technologies that make more derivatizations of pseudoUridine a reality. Its expertise in this field involves not only the previously reported four modified pseudoUridines but also other novel ones that have been in urgent demand during the outbreak.

BOC Sciences' bulk and quality production of pseudoUridines is a significant part of the COVID-19 campaign since it greatly eases the current pressing raw material supply issue for mRNA vaccine R&D. "Well, of course, we know how important pseudoUridines are in our vaccine development program. However, the procurement department was previously in trouble outsourcing raw materials owing to the pressure facing global factories and logistics," a regular customer of BOC Sciences remarked, "This problem of uncertainty in the supply chain was not resolved until we got connected with BOC Sciences who has the potent production capacity and impeccable project management system."

BOC Sciences is actively expanding its partnerships with a broader scope of customers, holding the vision that mRNA vaccine developers can be emancipated from the upstream supply worries and ultimately power up the fight against the epidemic.

About

BOC Sciences has become the largest supplier of pseudoUridines in the world with a significant production capacity. Currently, it actively gets engaged in the anti-epidemic campaign and is widely acclaimed for its unique contribution.

Contact Info:
Name: Alex Brown
Email: Send Email
Organization: BOC Sciences
Address: New York, USA
Phone: 1-631-485-4226
Website: https://nucleotech.bocsci.com/

Release ID: 89079447

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.